SCHEMBL6706777

SCHEMBL6706777

CC(C)c1ccc(-c2c(C(=O)O)cccc2C(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.52
TAS2R14 Q9NYV8 2/20 0.44
DHODH Q02127 2/20 0.42
RORC P51449 1/20 0.42
AKR1C3 P42330 4/20 0.41
AKR1C2 P52895 4/20 0.41
CTSS P25774 2/20 0.41
RAB9A P51151 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HIF1A Q16665 1/20 0.41
PTPN5 P54829 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CTSK P43235 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6705585 0.85 ALDH1A1 (0.44) FABP4AKR1C3AKR1C2CTSSPTPN5
SCHEMBL6703940 0.83 FABP4 (0.70) FABP4TAS2R14DHODHRORCMEN1
SCHEMBL6705876 0.81 TTR (0.51) DHODHRAB9AMEN1NPC1KMT2A
SCHEMBL4982052 0.79 MYC (0.51) FABP4DHODHRAB9ACYP2C9MEN1
SCHEMBL6698820 0.79 DHODH (0.46) FABP4DHODHRAB9AMEN1NPC1
SCHEMBL5937038 0.79 FABP3 (0.50) FABP4DHODHAKR1C3AKR1C2RAB9A
SCHEMBL11418034 0.78 DHODH (0.49) DHODHAKR1C2RAB9ACYP2D6CYP2C9
SCHEMBL6695055 0.75 FABP3 (0.53) FABP4DHODHRAB9AMEN1NPC1
SCHEMBL12303989 0.75 TAS2R14 (0.50) FABP4TAS2R14DHODHAKR1C3AKR1C2
SCHEMBL6708229 0.74 RXRA (0.40) FABP4TAS2R14DHODHAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003048121-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 WO claimed
US-20040024215-A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors SMITHKLINE BEECHAM CORPORATION 2004-02-05 US disclosed
WO-2003048121-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 WO disclosed
EP-1289971-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS GLAXO GROUP LIMITED (GB) 2003-03-12 EP disclosed
WO-2001092241-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS GLAXO GROUP LIMITED (GB) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024215-A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors APOB, APOL1, CETP FABP4 22/4885TAS2R14 3190/4885DHODH 3608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.